開發具有口服活性的高度選擇性卵泡刺激激素受體激動劑，且進行臨床前研究。其中對大鼠和狗的毒理學評估通過hjc黄金城進行

TOP5300 is an orally active follicle stimulating hormone receptor allosteric agonist that provides a preferred treatment for over 16 million infertile women of reproductive age in low complexity methods or in high complexity methods.

TOP5300 was evaluated in standard ADME, including Cytochrome P450 inhibition, clearance and pharmacokinetic profiles. Toxicological evaluations were performed in both rat and dog as the second species according to the guidance from FDA.  These assays were performed by Medicilon.

Reference:

Selva Nataraja, et al. Discovery and Preclinical Development of Orally Active Small Molecules that Exhibit Highly Selective Follicle Stimulating Hormone Receptor Agonism. Front Pharmacol. 2021 Jan 14;11:602593. doi: 10.3389/fphar.2020.602593.